Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient.

Regan S, Yang X, Finnberg NK, El-Deiry WS, Pu JJ.

Cancer Biol Ther. 2019;20(11):1389-1397. doi: 10.1080/15384047.2019.1647055. Epub 2019 Aug 18.

PMID:
31423878
2.

Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signatures.

Finnberg NK, Gokare P, Lev A, Grivennikov SI, MacFarlane AW 4th, Campbell KS, Winters RM, Kaputa K, Farma JM, Abbas AE, Grasso L, Nicolaides NC, El-Deiry WS.

Oncotarget. 2017 Aug 5;8(40):66747-66757. doi: 10.18632/oncotarget.19965. eCollection 2017 Sep 15.

3.

P53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression in response to thymidylate synthase (TS) targeting.

Gokare P, Finnberg NK, Abbosh PH, Dai J, Murphy ME, El-Deiry WS.

Sci Rep. 2017 Aug 29;7(1):9711. doi: 10.1038/s41598-017-09859-x.

4.

Tissue TGF-β expression following conventional radiotherapy and pulsed low-dose-rate radiation.

Meyer JE, Finnberg NK, Chen L, Cvetkovic D, Wang B, Zhou L, Dong Y, Hallman MA, Ma CC, El-Deiry WS.

Cell Cycle. 2017 Jun 18;16(12):1171-1174. doi: 10.1080/15384101.2017.1317418. Epub 2017 May 9.

5.

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Teye EK, Sido A, Xin P, Finnberg NK, Gokare P, Kawasawa YI, Salzberg AC, Shimko S, Bayerl M, Ehmann WC, Claxton DF, Rybka WB, Drabick JJ, Wang HG, Abraham T, El-Deiry WS, Brodsky RA, J Hohl R, Pu JJ.

Oncotarget. 2017 May 2;8(18):29887-29905. doi: 10.18632/oncotarget.15136.

6.

Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).

Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.

Clin Cancer Res. 2016 Dec 15;22(24):6192-6203. Epub 2016 Jun 15.

7.

Targeting of Chk2 as a countermeasure to dose-limiting toxicity triggered by topoisomerase-II (TOP2) poisons.

Gokare P, Navaraj A, Zhang S, Motoyama N, Sung SS, Finnberg NK.

Oncotarget. 2016 May 17;7(20):29520-30. doi: 10.18632/oncotarget.8790.

8.

ANIMAL MODELS OF CANCER BIOLOGY.

Yee NS, Ignatenko N, Finnberg N, Lee N, Stairs D.

Cancer Growth Metastasis. 2015 Dec 10;8(Suppl 1):115-8. doi: 10.4137/CGM.S37907. eCollection 2015. No abstract available.

9.

Agonists of the TRAIL Death Receptor DR5 Sensitize Intestinal Stem Cells to Chemotherapy-Induced Cell Death and Trigger Gastrointestinal Toxicity.

Finnberg NK, Gokare P, Navaraj A, Lang Kuhs KA, Cerniglia G, Yagita H, Takeda K, Motoyama N, El-Deiry WS.

Cancer Res. 2016 Feb 1;76(3):700-12. doi: 10.1158/0008-5472.CAN-15-2759. Epub 2015 Nov 25.

10.

Novel and Emerging Targeted Therapies of Colorectal Cancer.

Finnberg N, Gokare P, El-Deiry WS.

Curr Clin Pharmacol. 2015;10(4):279-98. Review.

PMID:
26548905
11.

Targeting TRAIL in the treatment of cancer: new developments.

Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS.

Expert Opin Ther Targets. 2015;19(9):1171-85. doi: 10.1517/14728222.2015.1049838. Epub 2015 May 25. Review.

PMID:
26004811
12.

TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess.

Idrissova L, Malhi H, Werneburg NW, LeBrasseur NK, Bronk SF, Fingas C, Tchkonia T, Pirtskhalava T, White TA, Stout MB, Hirsova P, Krishnan A, Liedtke C, Trautwein C, Finnberg N, El-Deiry WS, Kirkland JL, Gores GJ.

J Hepatol. 2015 May;62(5):1156-63. doi: 10.1016/j.jhep.2014.11.033. Epub 2014 Nov 28.

13.

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Condamine T, Kumar V, Ramachandran IR, Youn JI, Celis E, Finnberg N, El-Deiry WS, Winograd R, Vonderheide RH, English NR, Knight SC, Yagita H, McCaffrey JC, Antonia S, Hockstein N, Witt R, Masters G, Bauer T, Gabrilovich DI.

J Clin Invest. 2014 Jun;124(6):2626-39. doi: 10.1172/JCI74056. Epub 2014 May 1.

14.

The effects of antioxidants on gene expression following gamma-radiation (GR) and proton radiation (PR) in mice in vivo.

Finnberg N, Wambi C, Kennedy AR, El-Deiry WS.

Cell Cycle. 2013 Jul 15;12(14):2241-2247.

15.

Detection of DSS-induced gastrointestinal mucositis in mice by non-invasive optical near-infrared (NIR) imaging of cathepsin activity.

Finnberg NK, Liu Y, El-Deiry WS.

Cancer Biol Ther. 2013 Aug;14(8):736-41. doi: 10.4161/cbt.25094. Epub 2013 Jun 17.

16.

Inefficient boosting of antitumor CD8(+) T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions.

Zhi-Iong Ma J, Yang J, Qin JS, Richter A, Perret R, El-Deiry WS, Finnberg N, Ronchese F.

Oncoimmunology. 2012 Dec 1;1(9):1507-1516.

17.

High-resolution imaging and antitumor effects of GFP(+) bone marrow-derived cells homing to syngeneic mouse colon tumors.

Finnberg NK, Hart LS, Dolloff NG, Rodgers ZB, Dicker DT, El-Deiry WS.

Am J Pathol. 2011 Nov;179(5):2169-76. doi: 10.1016/j.ajpath.2011.07.028. Epub 2011 Oct 3.

18.

Death receptor 5 signaling promotes hepatocyte lipoapoptosis.

Cazanave SC, Mott JL, Bronk SF, Werneburg NW, Fingas CD, Meng XW, Finnberg N, El-Deiry WS, Kaufmann SH, Gores GJ.

J Biol Chem. 2011 Nov 11;286(45):39336-48. doi: 10.1074/jbc.M111.280420. Epub 2011 Sep 22.

19.

Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients.

Kline CL, Sheikh HS, Scicchitano A, Gingrich R, Beachler C, Finnberg NK, Liao J, Sivik J, El-Deiry WS.

Cancer Biol Ther. 2011 Oct 1;12(7):557-68. Epub 2011 Oct 1.

PMID:
21931273
20.

The relative contribution of pro-apoptotic p53-target genes in the triggering of apoptosis following DNA damage in vitro and in vivo.

Kuribayashi K, Finnberg N, Jeffers JR, Zambetti GP, El-Deiry WS.

Cell Cycle. 2011 Jul 15;10(14):2380-9. Epub 2011 Jul 15.

21.

Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras.

Navaraj A, Finnberg N, Dicker DT, Yang W, Matthew EM, El-Deiry WS.

Cancer Biol Ther. 2009 Dec;8(24):2417-44. Epub 2009 Dec 14.

22.

Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival.

Wambi CO, Sanzari JK, Sayers CM, Nuth M, Zhou Z, Davis J, Finnberg N, Lewis-Wambi JS, Ware JH, El-Deiry WS, Kennedy AR.

Radiat Res. 2009 Aug;172(2):175-86. doi: 10.1667/RR1708.1.

23.

Gamma-radiation (GR) triggers a unique gene expression profile associated with cell death compared to proton radiation (PR) in mice in vivo.

Finnberg N, Wambi C, Ware JH, Kennedy AR, El-Deiry WS.

Cancer Biol Ther. 2008 Dec;7(12):2023-33. Epub 2008 Dec 17.

24.

Studying p53-dependent cell death in vitro and in vivo.

Kuribayashi K, Finnberg N, El-Deiry WS.

Methods Enzymol. 2008;446:159-73. doi: 10.1016/S0076-6879(08)01609-1. No abstract available.

PMID:
18603121
25.

TRAIL death receptors as tumor suppressors and drug targets.

Finnberg N, El-Deiry WS.

Cell Cycle. 2008 Jun 1;7(11):1525-8. Epub 2008 Mar 24. Review.

PMID:
18469516
26.

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis.

Finnberg N, Klein-Szanto AJ, El-Deiry WS.

J Clin Invest. 2008 Jan;118(1):111-23.

27.

Selective TRAIL-induced apoptosis in dysplastic neoplasia of the colon may lead to new neoadjuvant or adjuvant therapies.

Finnberg N, El-Deiry WS.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4132-6. Review. No abstract available.

28.

Non-invasive fluorescence imaging of cell death in fresh human colon epithelia treated with 5-Fluorouracil, CPT-11 and/or TRAIL.

Finnberg N, Kim SH, Furth EE, Liu JJ, Russo P, Piccoli DA, Grimberg A, El-Deiry WS.

Cancer Biol Ther. 2005 Sep;4(9):937-42. Epub 2005 Sep 18.

29.

DR5 knockout mice are compromised in radiation-induced apoptosis.

Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, Burns TF, Ajuha H, Page R, Wu GS, Chen Y, McKenna WG, Bernhard E, Lowe S, Mak T, El-Deiry WS.

Mol Cell Biol. 2005 Mar;25(5):2000-13.

30.

p53-dependent induction of serine proteases in irradiated mouse colon.

Lin SW, Cook M, Finnberg N, Bernhard E, Baldwin D, El-Deiry WS.

Cancer Biol Ther. 2004 Dec;3(12):1290-7. Epub 2004 Dec 9.

PMID:
15684611
31.

Activating FOXO3a, NF-kappaB and p53 by targeting IKKs: an effective multi-faceted targeting of the tumor-cell phenotype?

Finnberg N, El-Deiry WS.

Cancer Biol Ther. 2004 Jul;3(7):614-6. Epub 2004 Jul 24. Review.

PMID:
15254408
33.

Characterizing the role of MDM2 in diethylnitrosamine induced acute liver damage and development of pre-neoplastic lesions.

Finnberg N, Silins I, Stenius U, Högberg J.

Carcinogenesis. 2004 Jan;25(1):113-22. Epub 2003 Oct 10.

PMID:
14555611
34.

Reduced ATM kinase activity and an attenuated p53 response to DNA damage in carcinogen-induced preneoplastic hepatic lesions in the rat.

Silins I, Finnberg N, Ståhl A, Högberg J, Stenius U.

Carcinogenesis. 2001 Dec;22(12):2023-31.

PMID:
11751435

Supplemental Content

Loading ...
Support Center